Tiziana Life Sciences (TLSA)
(Delayed Data from NSDQ)
$1.23 USD
+0.01 (0.82%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $1.23 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Tiziana Life Sciences Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 18 | 15 | 27 | 28 | 10 |
Income After Depreciation & Amortization | -18 | -15 | -27 | -28 | -10 |
Non-Operating Income | 0 | -1 | 1 | 0 | 0 |
Interest Expense | -1 | 0 | 0 | 0 | 0 |
Pretax Income | -17 | -15 | -27 | -28 | -10 |
Income Taxes | 0 | 0 | -3 | -2 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -18 | -15 | -23 | -26 | -9 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -18 | -15 | -23 | -26 | -9 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -18 | -15 | -27 | -28 | -10 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -18 | -15 | -27 | -28 | -10 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 104.06 | 102.65 | 97.93 | 169.07 | 332.97 |
Diluted EPS Before Non-Recurring Items | -0.17 | -0.15 | -0.24 | -0.11 | -0.03 |
Diluted Net EPS (GAAP) | -0.17 | -0.15 | -0.24 | -0.77 | -0.14 |
Fiscal Year end for Tiziana Life Sciences Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |